According to filings with the U.S. Securities and Exchange Commission, Avertix Medical is raising up to $28,411,917.00 in new funding. Sources indicate that as part of senior management Director, Taylor Andrew played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Avertix Medical
Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, were dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertixs Guardian is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

To learn more about Avertix Medical, visit http://www.avertix.com/
Avertix Medical Linkedin Page: https://www.linkedin.com/company/avertix/

Contact:
Taylor Andrew, Director
732-542-5551

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.